MiR-296-5p ameliorates deep venous thrombosis by inactivating S100A4

Deep venous thrombosis is one of the most common venous thromboembolic diseases and has a low cure rate and a high postoperative recurrence rate. Furthermore, emerging evidence indicates that microRNAs are involved in deep venous thrombosis. miR-296-5p is an important microRNA that plays a critical role in various cellular functions, and S100A4 is closely related to vascular function. miR-296-5p is downregulated in deep venous thrombosis patients, and its predicted target S100A4 is upregulated in deep venous thrombosis patients. Therefore, it was hypothesized that miR-296-5p may play a vital role in the development of deep venous thrombosis by targeting S100A4. An Ox-LDL-stimulated HUVEC and deep venous thrombosis mouse model was employed to detect the biological functions of miR-296-5p and S100A4. Dual luciferase reporter assays and pull-down assays were used to authenticate the interaction between miR-296-5p and S100A4. ELISA and Western blotting were employed to detect the protein levels of thrombosis-related factors and the endothelial-to-mesenchymal transition (EndMT)-related factors. The miR-296-5p levels were reduced, while the S100A4 levels were enhanced in deep venous thrombosis patients, and the miR-296-5p levels were negatively correlated with the S100A4 levels in deep venous thrombosis patients. miR-296-5p suppressed S100A4 expression by targeting the 3ʹ UTR of S100A4. MiR-296-5p knockdown accelerated ox-LDL-induced HUVEC apoptosis, oxidative stress, thrombosis-related factor expression, and EndMT, while S100A4 knockdown antagonized these effects in ox-LDL-induced HUVECs. S100A4 knockdown reversed the effect induced by miR-296-5p knockdown. Moreover, the in vivo studies revealed that miR-296-5p knockdown in deep venous thrombosis mice exacerbated deep venous thrombosis formation, whereas S100A4 knockdown had the opposite effect. These results indicate that elevated miR-296-5p inhibits deep venous thrombosis formation by inhibiting S100A4 expression. Both miR-296-5p and S100A4 may be potential diagnostic markers and therapeutic targets for deep venous thrombosis.

[1]  Lei Wang.  ELF1-activated FOXD3-AS1 promotes the migration, invasion and EMT of osteosarcoma cells via sponging miR-296-5p to upregulate ZCCHC3 , 2020, Journal of bone oncology.

[2]  Keyuan Zhou,et al.  MicroRNA-296-5p inhibits cell metastasis and invasion in nasopharyngeal carcinoma by reversing transforming growth factor-β-induced epithelial–mesenchymal transition , 2020, Cellular & molecular biology letters.

[3]  Kazumichi Yoshida,et al.  Calcium‐Binding Protein S100A4 Is Upregulated in Carotid Atherosclerotic Plaques and Contributes to Expansive Remodeling , 2020, Journal of the American Heart Association.

[4]  C. Reutelingsperger,et al.  Reactive Oxygen-Forming Nox5 Links Vascular Smooth Muscle Cell Phenotypic Switching and Extracellular Vesicle-Mediated Vascular Calcification , 2020, Circulation research.

[5]  F. Franconi,et al.  S100A4 Is a Biomarker of Tumorigenesis, EMT, Invasion, and Colonization of Host Organs in Experimental Malignant Mesothelioma , 2020, Cancers.

[6]  Ze Lu,et al.  Fusobacterium nucleatum promotes epithelial‐mesenchymal transiton through regulation of the lncRNA MIR4435‐2HG/miR‐296‐5p/Akt2/SNAI1 signaling pathway , 2020, The FEBS journal.

[7]  Tingting Wang,et al.  Overcoming Radioresistance in Tumor Therapy by Alleviating Hypoxia and Using HIF-1 Inhibitor. , 2020, ACS applied materials & interfaces.

[8]  M. Saegusa,et al.  S100A4/non-muscle myosin II signaling regulates epithelial-mesenchymal transition and stemness in uterine carcinosarcoma , 2019, Laboratory Investigation.

[9]  Zhen Zhang,et al.  IL (Interleukin)-6 Contributes to Deep Vein Thrombosis and Is Negatively Regulated by miR-338-5p , 2019, Arteriosclerosis, thrombosis, and vascular biology.

[10]  Lili Sun,et al.  Reciprocal enhancement of thrombosis by endothelial-to-mesenchymal transition induced by iliac vein compression. , 2019, Life sciences.

[11]  S. Jimenez,et al.  Endothelial to Mesenchymal Transition: Role in Physiology and in the Pathogenesis of Human Diseases. , 2019, Physiological reviews.

[12]  Hong Shen,et al.  Therapeutic strategies of thromboembolic events in patients with inflammatory bowel diseases , 2019, Medicine.

[13]  M. Grigorian,et al.  The Multifaceted S100A4 Protein in Cancer and Inflammation. , 2019, Methods in molecular biology.

[14]  Yuan Qiao,et al.  MicroRNAs: Pleiotropic Regulators in the Tumor Microenvironment , 2018, Front. Immunol..

[15]  A. Brill,et al.  Immune Factors in Deep Vein Thrombosis Initiation , 2018, Trends in immunology.

[16]  P. Poredos,et al.  Endothelial Dysfunction and Venous Thrombosis , 2018, Angiology.

[17]  Jun-fen Ma,et al.  Circulating microRNA expression and their target genes in deep vein thrombosis , 2017, Medicine.

[18]  Betty Y. S. Kim,et al.  S100A4 Is a Biomarker and Regulator of Glioma Stem Cells That Is Critical for Mesenchymal Transition in Glioblastoma. , 2017, Cancer research.

[19]  Anand M. Prabhakar,et al.  Advanced imaging in acute and chronic deep vein thrombosis. , 2016, Cardiovascular diagnosis and therapy.

[20]  W. Walther,et al.  S100A4 in Cancer Metastasis: Wnt Signaling-Driven Interventions for Metastasis Restriction , 2016, Cancers.

[21]  H. Matsui,et al.  Manganese superoxide dismutase promotes interaction of actin, S100A4 and Talin, and enhances rat gastric tumor cell invasion , 2015, Journal of clinical biochemistry and nutrition.

[22]  H. Ozkol,et al.  Roles of the Oxidative Stress and ADMA in the Development of Deep Venous Thrombosis , 2014, Biochemistry research international.

[23]  Yongjian Wu,et al.  MicroRNAs: important modulators of oxLDL-mediated signaling in atherosclerosis. , 2013, Journal of atherosclerosis and thrombosis.

[24]  O. Eickelberg,et al.  New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis , 2012, The Lancet.

[25]  G. Mælandsmo,et al.  Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer , 2012, BMC Cancer.

[26]  T. Wakefield,et al.  Critical review of mouse models of venous thrombosis. , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[27]  T. Loennechen,et al.  Dysregulation of Matrix Metalloproteinases and their Tissue Inhibitors by S100A4 , 2008, Connective tissue research.

[28]  Xueli Yuan,et al.  Endothelial-to-mesenchymal transition contributes to cardiac fibrosis , 2007, Nature Medicine.

[29]  K. Pavelka,et al.  S100A4 is expressed at site of invasion in rheumatoid arthritis synovium and modulates production of matrix metalloproteinases , 2006, Annals of the rheumatic diseases.